FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer

The FDA approved dostarlimab-gxly (Jemperli) for untreated locally advanced rectal cancer with dMMR/MSI-H. The approval, based on the AZUR-1 trial, showed 75% of patients avoiding surgery, chemotherapy, or radiotherapy. GSK's dostarlimab is the eleventh approval under the Commissioner’s National Priority Voucher program. The FDA noted potential immune system side effects. Further results will be presented at the 2026 ESMO Congress.

Original reporting
Published Oct 19, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 6:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer — source image
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

GSK's stock may react positively as the market incorporates the new indication, while competitors may see relative weakness.

02

Market read

First‑report FDA approval for a new rectal cancer indication, likely to move GSK stock and impact the oncology sector.

03

What to watch

Reimbursement negotiations and competition from other MSI‑H therapies may affect commercial success.

Relevance 7/10Novelty 9/10Timing: immediate

Background

The FDA's accelerated approval program allows earlier patient access to promising therapies based on surrogate endpoints.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA granted accelerated approval to GSK's dostarlimab (Jemperli) for untreated locally advanced dMMR/MSI-H rectal cancer.

Expected impact

upward pressure as investors price in the new indication and future revenue.

Evidence & confidence

Regulatory approval is a material catalyst; the therapy addresses an unmet need and may drive significant uptake.

Market effects

Strengthens the oncology immunotherapy sector and may pressure peers lacking similar approvals.

Positive for US and European biotech markets where GSK trades.

Adds to the pipeline of FDA‑approved cancer immunotherapies, influencing global biotech sentiment.

Counterpoint

Potential safety concerns and limited Phase 2 data could temper long‑term adoption.

Key entities

  • GSK

    Global healthcare company developing dostarlimab.

  • FDA

    U.S. Food and Drug Administration granting the approval.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.